COVID-19 and cellular senescence

Clemens A. Schmitt, Tamar Tchkonia, Laura J. Niedernhofer, Paul D. Robbins, James L. Kirkland and Soyoung Lee

Abstract | The clinical severity of coronavirus disease 2019 (COVID-19) is largely determined by host factors. Recent advances point to cellular senescence, an ageing-related switch in cellular state, as a critical regulator of SARS-CoV-2-evoked hyperinflammation. SARS-CoV-2, like other viruses, can induce senescence and exacerbates the senescence-associated secretory phenotype (SASP), which is comprised largely of pro-inflammatory, extracellular matrix-degrading, complement-activating and pro-coagulatory factors secreted by senescent cells. These effects are enhanced in elderly individuals who have an increased proportion of pre-existing senescent cells in their tissues. SASP factors can contribute to a ‘cytokine storm’, tissue-destructive immune cell infiltration, endotheliitis (endothelitis), fibrosis and microthrombosis. SASP-driven spreading of cellular senescence uncouples tissue injury from direct SARS-CoV-2-inflicted cellular damage in a paracrine fashion and can further amplify the SASP by increasing the burden of senescent cells. Preclinical and early clinical studies indicate that targeted elimination of senescent cells may offer a novel therapeutic opportunity to attenuate clinical deterioration in COVID-19 and improve resilience following infection with SARS-CoV-2 or other pathogens.

The coronavirus disease 2019 (COVID-19) pandemic is a continuing major threat to global health and the economy. Infections with SARS-CoV-2 and its variants of concern (VOC) evoke a broad spectrum of clinical manifestations, ranging from asymptomatic infections to disease associated with profound tissue damage, organ failure and death. The excessive release of pro-inflammatory cytokines, a condition termed ‘cytokine storm’ (see BOX 1 with glossary terms for further explanation), and massive immune stimulation, resulting in macrophage activation syndrome (MAS) (BOX 1), aberrant neutrophil activation or T cell hyperactivation, are characteristic features of severe COVID-19 (REFS. 3–4). Extensive efforts have been undertaken to reduce viral spread and avoid severe disease pathology, including the administration of antiviral agents such as Molnupiravir (EIDD-2801) or Paxlovid (PF-07321332) and, importantly, vaccines, most of which induce immune responses targeted at the SARS-CoV-2 spike protein. Another strategy is the mitigation of destructive hyperinflammation by using steroids such as dexamethasone, which has significantly reduced mortality rates, or treatment with other anti-inflammatory agents, for which clinical results have been mixed.

The recently reported promising clinical effects observed with the IL-1α/IL-1β blocker anakinra and the anti-IL-6 receptor antibodies tocilizumab and sarilumab confirm the critical role of overactive cytokine networks in COVID-19 (REF.15).

Although vaccines and previous infections largely protect against severe clinical courses of COVID-19 — particularly in the current phase of the pandemic, which is dominated by sublineages of the SARS-CoV-2 Omicron variant — there is still a significant unmet medical need for therapeutics to treat severe courses of disease in unvaccinated or immunosuppressed individuals as well as in elderly patients and patients with chronic disease conditions. Moreover, given the high global incidence of SARS-CoV-2 infections, no one can predict whether and when a distinct, much more virulent VOC might emerge.

Despite an advanced understanding of the molecular mechanisms underlying angiotensin-converting enzyme 2 (ACE2) receptor-mediated viral entry and viral propagation in susceptible host cells and new insights into innate and adaptive immune responses to SARS-CoV-2 infection, less is known about cause–consequence relationships between the primary virus infection and subsequent pivotal pathogenetic events that can collectively lead to organ failure. SARS-CoV-2-related lung disease is characterized by extensive activation of both M1-like and M2-like macrophages (BOX 1), infiltration by a heterogeneous spectrum of neutrophils, neutrophil extracellular trap (NET) formation, complement activation, and characteristic patterns of SARS-CoV-2-specific T cell immunity composed of predominantly IFNγ-releasing T helper 1 (T H1) cells with a central memory phenotype and perforin-expressing CD8+ T cells with an effector phenotype. This can lead to immunopathology, resulting in alveolar and capillary damage, including endotheliitis (also referred to as endothelitis) and endothelial cytolysis, fibrosis and widespread microthrombosis. Interestingly, the most destructive phase of immune activation often occurs when the viral mRNA is no longer detectable.

Disease manifestations of SARS-CoV-2 infection might, at least partially, be seen as a programmed cellular stress response to the initiating viral insult of the upper airway respiratory cells. Recently, it was found that SARS-CoV-2 can evoke a form of cellular senescence, virus-induced senescence (VIS) (BOX 1), through multiple mechanisms (REFS. 25–29) (FIG. 1).

Cellular senescence is a stress-inducible cellular state switch that includes terminal cell-cycle arrest and the acquisition of a senescence-associated secretory phenotype (SASP). The SASP is predominantly characterized by the secretion of pro-inflammatory cytokines and extracellular matrix-modifying factors and plays important roles in embryonic development, ageing, oncogene-evoked and cancer therapy-evoked insults, as well as tissue injury (see BOX 2 for details). In this Perspective, we propose that a propensity to senescence-governed immune escalation, which can be related to ageing or chronic...
Box 1 | Glossary terms used in this article

**Acute respiratory distress syndrome.** Is a life-threatening response to lung-damaging insults, leading to respiratory failure characterized by rapid onset of widespread inflammation and fluid leakage into the alveoli, thereby severely impairing alveolar gas exchange.

**Classic senescence response.** Is a full-featured senescence response composed of a terminal cell-cycle arrest, signs of DNA damage and enhanced DNA damage response signalling, elevated MAPK pathway activity, global genomic reorganization, and chromatin remodelling (such as ‘senescence-associated heterochromatin foci’), expansion of the lysosomal compartment and a pronounced senescence-associated secretory phenotype (SASP).

**Cytokine storm.** This is the secretion of vast amounts of largely pro-inflammatory cytokines, also known as cytokine release syndrome, that occurs in various hyperinflammatory disease contexts; it serves as an indicator and mediator of immune hyperactivation and subsequent immune-mediated tissue damage.

**Ki67 expression.** Is widely used in routine pathological investigation as a nuclear proliferation marker as its expression is strongly associated with cell division.

**Lipofuscin.** Also considered ‘age pigment’, is brownish-yellowish, electron-dense material that progressively accumulates in the lysosomes of postmitotic cells and hence plays some role as a senescence surrogate marker.

**M1-like and M2-like macrophages.** ‘M1’ and ‘M2’ are classifications historically used to define macrophages activated in vitro as pro-inflammatory (when ‘classically’ activated with IFNγ and lipopolysaccharides) or anti-inflammatory (when ‘alternatively’ activated with IL-4 or IL-10), respectively. However, in vivo macrophages are highly specialized, transcriptionally dynamic and extremely heterogeneous with regards to their phenotypes and functions, which are continuously shaped by their tissue microenvironment. Therefore, the M1 or M2 classification is too simplistic to explain the true nature of in vivo macrophages, although these terms are still often used to indicate whether the macrophages in question are more pro-inflammatory or anti-inflammatory.

**Macrophage activation syndrome.** Is an uncontrolled, mechanistically not fully elucidated, often life-threatening activation and proliferation of macrophages with a marked increase in circulating cytokines (see ‘cytokine storm’) in response to virus infections or other pro-inflammatory triggers.

**Paracrine senescence.** Is a form of secondary, full-featured senescence evoked by adjacent, primary senescent cells owing to their secretion of SASP factors with pro-senescent potential (for example, plasminogen activator inhibitor 1 (PAI1)).

**Pyroptosis.** Is a highly inflammatory mode of regulated cell death, which plays a role in the removal of intracellular pathogens such as viruses. Initiated by a large supramolecular complex termed the inflammasome, a specific subset of caspases triggers pro-inflammatory cytokine activation and eventual cell pore formation.

**scATACseq.** Single-cell assay for transposase-accessible chromatin-sequencing is a sequencing method used to assess genome-wide chromatin accessibility (for transcription factor binding, for instance) by probing open chromatin with a hyperactive transposase that inserts sequencing adapters selectively into open regions of the genome.

**Virus-induced senescence.** A stress-induced state switch of host cells in response to virus entry and propagation as the sensed cellular insult, comprised of a lasting cell-cycle arrest and an associated secretory response (termed SASP).

**Virus- evoked cellular stress**

VIS appears to be a universal stress response in host cells and can be induced by many different virus species. These include single-stranded and double-stranded DNA and RNA viruses belonging to the Retroviridae, Paramyxoviridae, Parvoviridae, Rhabdoviridae and Coronaviridae families, and has been explicitly shown for lentiviruses, adenov-associated viruses, vesicular stomatitis viruses and, notably, SARS-CoV-2 (REFS 28,29,34–38). The molecular mechanisms by which different viruses evoke cellular senescence appear to vary as both replication-competent and assembly-defective viruses that cannot produce intact virions can induce a senescence response, although this requires higher viral titres for replication-ineptent viruses.

For example, viruses such as the Merkel cell polyoma virus, HIV and SIV affect genome integrity, which can induce a senescence response. Respiratory syncytial or measles viruses enforce cell fusions, which act as cellular stress that can lead to VIS (REFS 14–16,39). This is also observed in SARS-CoV-2 infection, where the Delta variant was shown to be particularly fusogenic (REF 40).

Although senescence reportedly leads to enhanced expression of entry receptors for different viruses, with the underlying mechanisms and the spectrum of affected entry receptors yet to be elucidated (REF 37,41,42), it can also repress virus propagation, which is thought to be due to the enhanced release of interferons as part of the SASP (REF 43). Moreover, at least in certain settings, antiviral therapies may induce cellular senescence (REF 44). However, some agents that interfere with viral replication can also inhibit VIS responses. For example, this was shown for the reverse transcriptase inhibitor zidovudine in the context of retroviral infection and for the remdesivir derivative GS-441425, a viral RNA polymerase inhibitor, in the context of SARS-CoV-2 infection (REF 45, FIG. 1). Importantly, VIS reflects a ‘full-featured’ senescent state switch of host cells, accompanied by a pronounced SASP that is detectable by a typical set of molecular markers (BOX 2).

The direct induction of senescence through infection with SARS-CoV-2 was demonstrated in vitro with a SARS-CoV-2-susceptible kidney cell line (Vero) as detected by an increase in lipofuscin (BOX 1), the secretion of SASP factors, including IL-1β, IL-6 and IL-8, and the DNA damage mark γH2A.X, as well as a loss of Ki67 expression (BOX 1). It is not entirely clear whether virus propagation stress or specific viral molecular components induce VIS. Interestingly, isolated recombinant S protein has been shown to increase the SASP in senescent ACE2-expressing cells (REF 29), similar to other pathogen-associated molecular patterns such as LPS (REF 46). However, whether the internalization of the S protein alone would suffice to induce senescence in non-senescent cells remains to be determined. Moreover, an elevated expression of the ACE2 receptor, which could contribute to enhanced susceptibility to SARS-CoV-2 in the elderly, became detectable in primary human lung epithelial cells in vitro in response to the SASP from pre-adipocytes or endothelial cells that had become senescent owing to ageing (REF 37). Senescent cells also express elevated levels of Toll-like receptor 3 (TLR3), which can detect SARS-CoV-2 viral RNA in endosomes. It is therefore conceivable that
SARS-CoV-2 infection of senescent cells may amplify their pro-inflammatory SASP, potentially inducing a positive feedback loop in a VIS-dependent manner29 (fig. 1).

The programmed VIS response is morphologically and transcriptionally largely indistinguishable from other types of senescence, in particular from oncogene-induced senescence28,46,47. It is also similar to the senescence induced by the retrovirus-related endogenous retrotransposon LINE-1 (refs. 48,49). Importantly, in vitro experiments showed that cells that lack functional p53 or overexpress the H3K9me3 demethylase JMJD2c46,50 — which therefore cannot enter senescence in response to pro-senescent oncogenes such as Ras-G12V or Braf-V600E46,51 — also failed to enter VIS and lacked a SASP upon infection with SARS-CoV-2 (REF. 28). This demonstrates that SARS-CoV-2-related cytokine production by infected cells is dependent on an intact capacity of these cells to enter cellular senescence. Additional experiments in SARS-CoV-2-susceptible but genetically senescence-compromised animal models are needed to confirm this observation in vivo.

Cells that undergo VIS show signs of DNA damage such as γH2A.X foci. Such foci were also detected in epithelial and endothelial cells from the lungs of patients with COVID-19 (REF. 52), and are presumably caused by an increase in reactive oxygen species (ROS) produced by mitochondria. In turn, lowering cellular ROS levels with N-acetyl-cysteine in in vitro VIS models profoundly reduced DNA damage foci and senescence-associated β-galactosidase (SA-β-gal) reactivity (BOX 3).

Of note, mitochondrial outer membrane shedding has been reported in response to MeSARS-CoV-2 ACE2 Mitochondrion Remdesivir TLR cGAS–STING IRF3 ROS H3K9me3 TF Promoter e.g. E2F target genes DNA damage foci (γH2A.X) Cell-cycle inhibitors e.g. p16INK4a, p21CIP1 • Pro-inflammatory factors (e.g. IL-1β, IL-6, IL-8) • ECM-degrading factors (e.g. MMP1, MMP3) • Complement-activating factors • Pro-coagulatory factors (e.g. Serpine1, THBS1, TIMP1) • Pro-fibrotic (e.g. TGFβ) • Pro-survival networks BCL-2 family proteins • Navitoclax (Venetoclax) • Fisetin • Quercetin (+ Dasatinib)

Fig. 1 | Senescence-modulated host cell responses upon SARS-CoV-2 infection. SARS-CoV-2 cellular entry induces senescence-typical transcriptional responses (see also BOXES 2 and 3), in both non-senescent or pre-existing senescent cells via viral replication stress, reactive oxygen species (ROS) production and cellular stress sensors such as toll-like receptor 3 (TLR3) and cGAS-STING signalling. Virus-induced senescence is characterized by senescence-associated, H3K9me3-positive heterochromatin foci (repressing, among others, S-phase-promoting E2F target genes), marks of DNA damage (that is, γH2AX foci), the induction of cell-cycle inhibitors such as p16INK4a and p21CIP1, and pro-inflammatory, extracellular matrix-degrading, complement-activating, pro-coagulatory and pro-fibrotic senescence-associated secretory phenotype (SASP) factors (predominantly via IRF3, NF-κB and C/EBPβ transcription factors) that exacerbate tissue-destructive host immunity and potentiate the burden of senescent cells through paracrine and endocrine spread of senescence27–29,44 and may include elevated angiotensin-converting enzyme 2 (ACE2) expression11. Notably, pro-survival mechanisms selected for in stressed senescent cells, among them induction of anti-apoptotic BCL-2 family members and survival signalling-enhancing kinase networks involving, for example, SRC family kinases, are attractive targets for the selective pharmacological elimination of these cells; such agents are termed ‘senolytics’. ECM, extracellular matrix; MMP, matrix metalloproteinases; TF, transcription factors.
Senescence was originally observed in cells that have exhausted their proliferative potential owing to the critical erosion of their telomeres. This process occurs during ageing and disease as well as at critical developmental steps in embryogenesis. Importantly, it is also an essential component of wound healing, indicating its tissue-protective and tissue-restoring role if it occurs at an adequate level and at the right time. Cellular insults, especially DNA damage but also other severe functional impairments, during tissue injury halt proliferation, which ensures that only intact cells contribute to the parenchymal cell pool. Driven by the cGAS–STING pathway and NF-kB and C/EBPβ signalling in response to DNA damage, senescent cells typically activate a vast, largely pro-inflammatory secretome that constitutes the senescence–associated secretory phenotype (SASP), which operates as a central component of wound healing but also causes tissue pathology. Regardless of the initiating stress, ‘full-featured’ senescence locks the cells into an essentially terminal growth arrest, typically accompanied by the release of predominantly NF-kB-driven pro-inflammatory cytokines (for example, IL-1α/β, IL-6 and IL-8) and chemokines (such as CCL2 or CXCL10), extracellular matrix-remodelling peptides (among them matrix metalloproteinases (MMPs), serpins and thrombospondins), reactive metabolites, bradykinins and prostanoids, and secreted non-coding, potentially tissue-destructive nucleotides (such as microRNAs or mitochondrial DNA). SASP-mediated paracrine (secondary) senescence ensures that critically damaged but not primarily senescent cells also stop dividing — normally a tissue-safeguard principle that may also lead to paracrine senescence of non-damaged parenchymal cells in pathological settings with an excessive production of SASP factors. SASP factors, such as MMP1 and MMP3, digest extracellular matrix barriers and attract immune cells to clear up cellular debris and, if present, microbial pathogens. Once exogenous stresses are resolved, functional tissue cellularity might be replenished by senescence-reprogrammed cells, which acquired stem cell-like capacity and may occasionally re-enter the cell cycle. Cellular senescence also occurs in other pathological stress scenarios, such as profound metabolic deregulation, the activation of oncogenes or cancer therapy-confferred cell damage, which function as a barrier to tumour development or as an alternative effector mechanism to treatment-induced apoptosis. Hence, senescence plays a critical role in tissue homeostasis, bearing the risk that chronically senescent cells, owing to their ongoing secretion of pro-inflammatory factors and their reprogrammed nature, account for detrimental biological outputs, implying that their selective removal can be beneficial.

The identification of senescent cells and their discrimination from other cell-cycle arrest, such as quiescence, are confounded by the phenotypic heterogeneity of the senescent cell state, thereby necessitating the analysis of multiple markers.

Senescence-associated DNA damage is sensed via the cGAS–STING pathway, which activates the transcription factors interferon regulatory factor 3 (IRF3) and NF-kB, thereby inducing an interferon and SASP response. Although cGAS–STING inhibitors have limited impact on primary VIS, they can reduce the SASP and its subsequent non-cell-autonomous effects. Lasting cGAS–STING activation in response to SARS-CoV-2 infection was recently confirmed to drive type 1 interferon responses and the secretion of other pro-inflammatory cytokines, such as IL-1α, IL-6 and tumour necrosis factor (TNF), by CD163+ macrophages and damaged lung endothelial cells in patients with severe COVID-19.

Notably, in vitro experiments showed that cells that were engineered to be unable to undergo senescence failed to activate the cGAS–STING pathway in response to viral infection. These observations indicate that viral entry causes high levels of cytokine secretion in host cells via the induction of VIS.

**Senescence in patients with COVID-19**

If VIS is of relevance as a cellular response to SARS-CoV-2 infection, then signs of cellular senescence should be detectable in ACE2-expressing ciliated epithelial cells of the upper airway mucosa — the site of primary virus–host encounter and viral replication — in patients with COVID-19. In general, the definitive demonstration of cellular senescence in vivo is a long-standing and challenging goal in the field because no single marker exists that defines senescence. In addition, cryopreserved clinical samples from patients with COVID-19 cannot be analysed without virus-inactivating fixation, thereby precluding their use for enzymatic assays such as SA-β-gal staining in situ. Nevertheless, when comparing samples of nasopharyngeal mucosa from patients with COVID-19 to pre-pandemic biopsy samples from individuals without a manifest respiratory tract infection, a panel of senescence markers was shown to robustly discriminate these two groups, with significantly higher reactivity in samples from patients with COVID-19. Specifically, senescence markers, such as p16INK4a, p21CIP1, H3K9me3 and lipofuscin (detected by the GLI13-SenTrAmp™ reagent in fixed tissues), as well as IL-8 (a component of the SASP) were markedly elevated in samples from the upper respiratory mucosa from patients with COVID-19.

Collectively, these observations indicate that VIS may persist beyond the initial infection and may be further aggravated by SASP-mediated paracrine spreading of senescence (paracrine senescence; BOX 1). The results are also consistent with the observed gradient of SARS-CoV-2 infectivity, where proximal pulmonary epithelial cells from patients with COVID-19 show higher levels of infection compared to cells from the distal respiratory tract. Moreover, these findings might explain, at least in part, the limited clinical efficacy of convalescent plasma in preventing severe COVID-19 given that the severe course of disease is thought to be caused by immune-mediated tissue damage independent of persistent virus.

Bulk and single-cell transcriptomic analyses further support the concept that SARS-CoV-2-triggered senescence drives pathology in COVID-19. Ciliated epithelial cells of the upper and lower airway mucosa of patients with COVID-19 displayed elevated levels of transcription of p16INK4a and various SASP factors. Moreover, lungs from patients who died from severe COVID-19 showed higher levels of p16INK4a-positive cells compared to lungs from individuals who died from other causes. The levels of SASP-typical cytokines and extracellular matrix-active proteases as well as SASP-related pro-coagulant and complement-activating factors (such as IL-1α, IL-6, CC-chemokine ligand 2 (CCL2), also known as MCP-1, CXC-chemokine ligand 10 (CXCL10), matrix metalloproteinase 9 (MMP9), plasminogen activator inhibitor 1
(PAI1, encoded by SERPINE1) and metalloproteinase inhibitor 1 (TIMP1)) were also strongly elevated in the serum of patients with COVID-19 compared to healthy controls [28,61]. Importantly, WHO-graded clinical severity of COVID-19 correlated positively with increasing concentrations of the pro-inflammatory SASP cytokine IL-6, the coagulation-related SASP representative SERPINA3 and D-Dimer-based clotting markers [28]. In particular, patients with COVID-19 who had detectable microthrombosis in their lungs presented with more pronounced levels of SASP-typical factors [28], giving rise to the hypothesis that more extensive senescence underlies more profound COVID-19 pathobiology.

Macrophages in senescence spreading

Importantly, the senescent state can spread to non-senescent and, potentially, to non-infected cells as the increase in SASP evoked by viral infection can lead to the induction of paracrine senescence [28,61]. This observation was further supported by single-cell analyses that detected senescence marker profiles in cells that were not susceptible to primary SARS-CoV-2 infection owing to the lack of ACE2 expression [28]. We suspect that senescent cells acutely reinforce systemic inflammatory responses to pathogens and facilitate the spread of senescence, a hypothesis termed the ‘SASP amplifier/rheostat model’ [27,28]. This model might also explain the increased risk of a cytokine storm and adverse outcomes after SARS-CoV-2 infection in the elderly or in individuals with chronic conditions associated with an increased burden of senescent cells such as obesity, diabetes or previous chemotherapy. A central aspect of severe COVID-19 is the MAS [27]. Consistent with the recruitment of macrophages to VIS cells within the upper airway mucosa, the macrophage chemoattractant CCL2 and other macrophage-recruiting chemokines were identified as prominent components of the SASP of VIS cells [24,73]. Recruited macrophages may clear some of the spread of senescence, a hypothesis termed the ‘SASP amplifier/rheostat model’ [27,28]. This finding that SARS-CoV-2 triggers a profibrotic response in CD14+CD163+ macrophages, which promotes manifest pulmonary fibrosis and acute respiratory distress syndrome (Box 1), complements these observations and further underscores the previously established link between cellular senescence and fibrosis in the lung via pro-fibrogenic SASP components [24,73]. Moreover, using a combination of single-cell RNA sequencing, mass cytometry and single-cell assay for transposase-accessible chromatin sequencing (scATAC-seq; Box 1) of blood samples from young and elderly individuals as well as patients with COVID-19, it was found that coronavirus susceptibility genes, among them CD414, CD26 and ANPEP (encoding aminopeptidase N; see REF. [82] for details), are upregulated with age. Additionally, SARS-CoV-2 infection was shown to induce polarization of peripheral blood immune cell subsets that is typical for ageing and includes the expression of genes associated with inflammation and senescence [28]. Specifically, the authors reported T cell polarization from naive and memory cell populations to effector, cytotoxic, exhausted and regulatory T cell populations, and found increased levels of inflammatory monocytes in the blood of elderly patients with COVID-19. Collectively, the data indicate that activated monocytes and decreased T cell activity characterize hyperinflammation in severe COVID-19.

Notably, although activation status, pro-inflammatory M1-like polarization and mobility of macrophages make it compelling to view these as senescence-primed messengers that further spread senescence in a paracrine manner in the lungs or systemically [28], it is still debated whether the macrophages enter a classic senescence response (Box 1) as opposed to a senescence-like condition characterized by the secretion of factors typical for the SAP [24,78]. Moreover, it was recently shown that monocytes and macrophages not only act as cytokine-releasing sensors of SARS-CoV-2-infected cells but that a small fraction of macrophages is susceptible to Fcγ receptor-mediated SARS-CoV-2 uptake and subsequent termination of virus replication via inflammasome activation and IL-1β-induced pyroptosis (Box 1). These features partially overlap with the senescence-like and SASP-reminiscent condition described here [28,82]. More detailed profiling, dynamic tracing and functional analyses are required to delineate the roles of senescence-marker-positive tissue-resident versus senescence-marker-positive infiltrating macrophages and circulating

Box 3 | Markers of senescence

Compared to their normal counterparts, senescent cells are enlarged, have a more granule-rich cytoplasm and appear to exhibit vanishing cell borders under light microscopy. Their typically expanded lysosomal compartment, reflecting enhanced autophagy/cytotoxic activity owing to senescence-associated secretory phenotype-related proteotoxic stress (REFS. [29,30]), forms the basis for the senescence-associated β-galactosidase (SA-β-gal) assay. This assay detects senescence-enhanced lysosomal lactosidase activity at a suboptimal, acidic pH, which is a condition that achieves best discrimination from non-senescent cells [28]. Beyond the ‘gold-standard’ SA-β-gal assay in its classic blue-stained end point form in fixed cells or as a fluorescence-based variation applicable to viable cells, there is no single senescence–defining, highly sensitive and specific marker of the senescence condition; hence, numerous markers are typically applied to collectively label a cell status as being senescent [28,30]. Among the most robustly established and widely applied markers in this regard are the cell-cycle inhibitors p16INK4a and p21Cip1, signs of DNA damage such as histone variant H2AX phosphorylated at its serine 139 (γH2AX), hypophosphorylated (that is, G1-phase–reminiscent) retinoblastoma (Rb) protein, activated MAPK signalling (such as phospho-ERK1/ERK2), and the transcriptionally repressive lysine 9-trimethylated histone H3 (H3K9me3) mark [31]. DAPI (4,6-diamidino-2-phenylindole)-dense senescence-associated heterochromatin foci indicate the profound epigenomic reorganization observed in senescent cells [31,32]. The Rb/E2F-mediated formation of H3K9me3-containing senescence-associated heterochromatin foci accounts for the stable senescence G1-phase arrest via the transcriptional repression of 5-phase-promoting E2F target gene promoters, thereby turning off genes, such as CDK2 or CCND2, that are flanked by decreased expression of the proliferation marker Ki-67 (REFS. [47,50,217]).
monocytes as well as the poorly understood functional consequences of paracrine senescence on distinct resident or mobile T cell subsets. Notably, age-related immunosenescence, a term often used to describe immune dysfunction in the elderly, seems to enhance COVID-19 severity via T cell-mediated cytotoxicity directed at virus-infected or otherwise altered cells. Moreover, SASP factors attract other immune cells and excessive activation of these cells can result in direct or indirect cytotoxicity at lung epithelial and endothelial cells. Specifically, VIS-driven features of severe, tissue-destructive coronavirus disease 2019 (COVID-19) include endothelial cell senescence, complement-mediated cytosis of endothelial cells, neutrophil extracellular trap (NET) formation, platelet activation and microthrombosis, and, presumably, SASP-enhanced T cell-mediated cytotoxicity towards alveolar epithelial cells (AECs) I and II. Pre-existing senescent, virus-induced senescent and secondary SASP-induced senescent cells are depicted in blue. See main text for details.

**Senescence-induced COVID-19 pathology**

Despite the strong correlation between the extent of senescence (including VIS) and COVID-19 severity, a causal relationship between these processes is yet to be demonstrated. Based on the concept that the SASP links virus-evoked and pre-existing cellular senescence to macrophage priming and to specific pathognomonic features, such as endothelial cell senescence and complement-mediated cytosis, NET formation, platelet activation and microthrombosis, in the damaged lung and other organ systems of patients with COVID-19, functional in vitro assays...
have been developed that can reproduce the aforementioned cellular responses to SARS-CoV-2 infection. For example, it was demonstrated that exposure to the supernatant of VIS cells induced macrophage activation that was marked by an M1-like polarization profile, CD86 upregulation and signs of secondary macrophage senescence as detected by SA-β-gal staining and senescence-typical gene expression. By contrast, the culture supernatant from equally virus-infected but senescence-incapable cells failed to evoke these cellular effects.

Another hallmark of COVID-19 is widespread thrombo-occlusive microangiopathy, which comprises lymphocytic endothelialitis with endothelial damage, platelet activation and capillary microthrombi. Neutrophils contribute to thrombosis by ejecting DNA, leading to intravascular net structures that activate platelets. All of these individual components were recapitulated in vitro and mechanistically dissected as senescence-activated. Specifically, conditioned medium from senescent cells that is rich in SASP-associated factors evoked paracrine senescence in endothelial cells or triggered their complement-mediated cytolysis, promoted NET formation by neutrophils, activated platelets, and accelerated clotting. These effects represent highly disease-relevant components of COVID-19–related immunothrombosis, which were detected to a much lesser extent if the supernatant from virus-infected but senescence-resistant cells was tested (Fig. 2). Of note, complement activation has recently been shown to aggravate tissue injury in patients with COVID-19 by inducing excessive T cell cytotoxicity via immune complex-induced and T cell receptor-independent degranulation, thereby potentially linking VIS and the SASP to uncontrolled T cell-mediated tissue damage. Overall, these in vitro observations suggest an essential, secretome-dependent role of VIS and senescence in general in the pathobiological manifestation of the infection.

**Senolytic strategies**

VIS cells, pre-existing senescent cells in the elderly and in those with underlying conditions, and SASP-induced secondary senescent cells appear to play a key role in the development of severe COVID-19. If cellular senescence is indeed a causative component of severe COVID-19, then the early elimination of senescent cells would be expected to attenuate disease severity.

This would confirm that senescent cells are a pivotal trigger of rapidly uncontrolled SASP-governed hyperinflammation in patients with severe COVID-19, thus expanding current therapeutic strategies. In addition to VIS, the burden of pre-existing senescent cells that is associated with older age or with chronic diseases, even in younger individuals, could also represent a key target to reduce complications and mortality in patients with COVID-19 (REFS 93–95).

Targeting senescent cells is increasingly viewed as a novel opportunity for delaying, preventing, alleviating or treating a wide spectrum of human diseases, among them age-related disorders, cancer and, now, viral infections with profound hyperinflammatory tissue damage, with early clinical trials currently running in many of these indications (REFS 94–97). A fundamental property and dependency of senescent cells is their protection from apoptotic death despite the stresses they encounter. Hence, a characteristic shared across senescent cells, especially those with a profound SASP, is their enhanced insensitivity to pro-apoptotic signals, which is mediated via upregulation of anti-apoptotic BCL-2 family members or kinases that promote pro-survival signalling — collectively referred to as senescent cell anti-apoptotic pathways (SCAPs) (REFS 98–99).

The SCAPs vary between different types of senescent cells (for example, between senescent human endothelial cells versus fat cell progenitors). In addition to BCL-2 family members, SCAPs are mediated by SRC family tyrosine kinases as well as pro-survival pathways related to serpin, heat shock protein and p21CIP1 (REFS 95–98). Indeed, the expression of BCL-xL and BCL-w and the activity of SRC, AKT and p38 kinases were found to be elevated in retrovirus-infected fibroblast models of VIS, in SARS-CoV-2–infected hamsters and in patients with COVID-19 (REF 99). This suggests therapeutic opportunities in COVID-19 for senolytic agents that interfere with SCAPs, thereby inducing apoptosis in VIS cells and in pre-existing senescent and secondary senescent cells. Drugs that have been shown to be effective in killing senescent cells in various clinical and preclinical models are of particular interest: these include the investigational BCL-xL and BCL-w inhibitor navitoclax (ABT-263) (REFS 99,100,101), BCL-xL-degrading proteolysis-targeting chimeric proteins with reduced platelet toxicity (REFS 102,103), and the kinase-inhibiting flavonoids fisetin and quercetin (REFS 99,100,101), the latter typically employed in combination with the SRC kinase inhibitor dasatinib (REFS 100,101,102,103).

**In vitro findings with senolytics in VIS.** Navitoclax, fisetin, and a combination of dasatinib and quercetin demonstrated significant cytotoxic activity against VIS cells (including human nasal epithelial cells exposed to SARS-CoV-2) in vitro, leaving uninfected or virus-infected but genetically senescence-incapable cells virtually unaffected. Importantly, the SARS-CoV-2 Alpha and Beta variants elicited a significantly stronger pro-inflammatory SASP upon infection compared to the ancestral SARS-CoV-2 strain, and these VIS cells exhibited excellent susceptibility to the aforementioned senolytics in vitro, comparable to cells infected with the ancestral virus. Additional investigations are needed to determine the relevance of senescence-related and SASP-related pathophysiology induced by Delta and Omicron variants given their distinctly different degrees of clinical severity (REF 104). Of note, senescent cells have enhanced activity of the apolipoprotein B mRNA-editing catalytic polypeptide-like (APOBEC) enzymes. Given that APOBEC enforces viral mutagenesis, it is also conceivable that host cell senescence actually promotes the generation of new SARS-CoV-2 variants (REFS 104,105).

A machine learning–based assessment of 45 FDA-approved drugs for their potential to be repurposed as antiviral agents in COVID-19 failed to predict a significant direct anti-viral activity of navitoclax and dasatinib, further underscoring that the mode of action of these agents in COVID-19 might be indirect, for example, through the selective elimination of senescent cells (REF 106). However, given the complexity of virus entry and replication, additional direct anti-viral activity cannot be excluded for any of the candidate senolytics tested and was reportedly observed upon quercetin pre-treatment (REF 107). Thus, to what extent the cytotoxicity exerted by anti-viral compounds is due to their direct interference with viral propagation or rather relates to VIS as a state-specific vulnerability of the host cell needs to be dissected in appropriate model systems, including the use of in vitro tests using cells that are genetically incapable of undergoing senescence. Given the broad deregulation of prominent pathways such as NF-kB, MAPK, ROS, JAK–STAT, p53–p21CIP1 and RB–p16INK4a in senescent cells in general and in VIS cells in particular, there is an encouragingly large and growing list of additional compounds that may indeed have senolytic potential in COVID-19 (REFS 104,105,108).
In vivo testing of senolytics in COVID-19.

Importantly, animal models of SARS-CoV-2 infection, such as the Syrian golden hamster (these animals typically have a mild course of disease) and the Roborovski dwarf hamster, as well as mice transgenic for human ACE2 (these have a more severe, typically fatal course of disease), implicated VIS as a feature of both mild and severe COVID-19, especially as a central driver in the latter, and highlighted the clinical potential of senolytics as a novel interventional therapeutic strategy. Particularly pronounced effects were observed in the Roborovski dwarf hamster model, where treatment with a combination of dasatinib and quercetin resulted in significantly attenuated disease features with respect to the overall pneumonia score, bronchial epithelial hyperplasia and alveolar damage. Strikingly, the broadly elevated levels of SASP—typical cytokines and interleukins — among them granulocyte colony-stimulating factor (G-CSF), IFNγ, IL-1α, IL-7, IL-17A, TNF and vascular endothelial growth factor (VEGF) — that were detected (despite the challenge to do this at the protein level in hamsters) in the serum of infected animals, were reduced by all agents tested to levels that were virtually indistinguishable from those in uninfected animals. In animal models of fatal COVID-19, senolytic regimens based on flavonoids, such as dasatinib and quercetin combination or fisetin, enhanced survival rates. Targeting of the cGAS–STING axis, which induces type I interferons and other SASP factors, with the small-molecule STING inhibitor H-151 had a SASP-suppressing, senomorphic effect and led to reduced lung pathology and prolonged survival in a human ACE2-transgenic mouse model of COVID-19. These observations provide further evidence for the pathogenic connection between senescence, SASP and severe COVID-19. Similarly, the inhibition of pro-inflammatory JAK signalling in the same model was shown to attenuate pathogenesis by reducing the infiltration of monocytes to the lungs. Age-related elevations of eicosanoid levels, especially prostaglandin D2 (PGD2), were detected in mouse models of SARS-CoV infection. The levels of PGD2 and related prostaglandins were also found to be increased in older individuals and in individuals infected with SARS-CoV-2. These prostaglandins are known to promote senescence and the SASP. In turn, genetic or pharmacological blockade of eicosanoid signalling was shown to protect aged mice from severe COVID-19, unveiling another mechanism by which inflammation, senescence, ageing and severe COVID-19 appear to be linked.

Therapeutic targeting of pre-existing senescent cells was also addressed in a model of coronavirus infection in aged mice. A cohort of aged INK-ATTAC transgenic mice, in which cells with high INK4a promoter activity, which is indicative of senescence, can be forced to undergo apoptosis, exhibited increased resilience to pathogens, including the mouse hepatitis virus (MHV, a mouse β-coronavirus), when p16INK6-high senescent cells were subjected to ATTAC-dependent depletion. Of note, the therapeutic benefit was evident not only if the senescent cell burden was reduced prior to infection but also following infection, consistent with an increased burden of senescent cells that persists following pathogen encounter.

The central role of senescent cells and the potential of senolytics as therapeutics were further investigated in aged specific-pathogen-free mice that were exposed to pet-store mouse pathogens, including MHV, termed a ‘normal microbial experience’ (NME). Nearly all of the aged mice exposed to NME died within 2 weeks, whereas there was no mortality observed in younger mice. Within 7 days following NME exposure, the expression of senescence marker genes (such as p16INK6 and p21) and SASP factors (such as IL-6, CCL2 and TNF) in liver, lung and kidney significantly increased in old mice compared to young mice. Treatment before and/or following NME exposure with the senolytic fisetin or the combination of dasatinib and quercetin reduced mortality. This is consistent with the adverse effects of an increased senescent cell burden with age and the lethal spread of senescence and inflammation following pathogen exposure, possibly through both VIS and the exacerbated tissue-destructive SASP caused by pathogen-associated molecular patterns. Notably, the mitigating activity observed when these agents were applied prior to NME exposure reflects a reduction of the pre-existing load of senescent cells, and not a direct antimicrobial mechanism, as the key mode of action.

Further corroborating and extending these preclinical findings to the human condition, two randomized clinical trials (NCT04578158 and NCT04861298) that, in addition to standard care, used a special formulation of quercetin with enhanced oral bioavailability as an early intervention in patients with mild COVID-19 symptoms, met their clinical end points. Specifically, a collective analysis of both trials demonstrated a significantly better outcome in terms of avoiding hospitalization, need for oxygen, referral to the intensive care unit and death. Of note, a recent clinical pilot study exploring a lecithin-based formulation of quercetin in combination with dasatinib as a senolytic treatment for idiopathic pulmonary fibrosis, an age-related and senescence-associated disease also occurring as a fibrotic complication in the course of COVID-19, showed encouraging signals of clinical improvement as evaluated by walk distance, speed and coordination tests, demonstrating the feasibility of this approach.

The clinical trials underscored that quercetin exerts meaningful senolytic activity when tested as a single agent in individuals with SARS-CoV-2 infection and appeared to have relevant clinical potential to prevent severe COVID-19. Several other randomized clinical trials are currently investigating the use of fisetin in patients with COVID-19 (NCT04476953, NCT04537299 and NCT04771611). These trials examine whether fisetin decreases SARS-CoV-2 morbidity and mortality in PCR-positive older individuals (as well as in younger patients with pre-existing cellular senescence-associated comorbidities, including diabetes, obesity, cardiovascular disorders or chronic lung diseases). If successful, larger randomized studies with optimized dosing schedules will be needed to establish senolytics as preventive or early interventional treatments for patients with severe COVID-19.
vaccinated individuals because they tend to be less frequently monitored when local regulations do not require testing. It is becoming increasingly clear that community protection owing to reduced viral loads in infected but fully vaccinated individuals is diminishing over time\(^\text{106}\), thereby facilitating further outbreaks and the rapid expansion of new VOCs\(^\text{106,165}\). The fact that viral entry and replication occur despite successful vaccination is interesting as VIS would be the assumed consequence and could trigger a cytokine storm potentially leading to severe COVID-19. The fact that this is typically not the case might be either owing to reduced viral replication and a limited viral load that does not elicit a significant senescence response and/or may be a consequence of vaccine-evoked T cell responses.

Unlike neutralizing antibodies that inhibit virus entry but require high levels to fully protect, SARS-CoV-2-specific T cells cannot block primary host cell infection. However, pre-existing SARS-CoV-2-specific cytotoxic T cells can selectively eliminate infected cells — similar to the removal of VIS cells by early senolytic intervention. Hence, such intrinsic 'T cell immunity-based senolysis' might interrupt a potentially deleterious cytokine cascade upon SARS-CoV-2 infection in vaccinated individuals, possibly even in those with a compromised humoral but intact cellular, and hence discordant, immune response. Such discordance is frequently detected following SARS-CoV-2 infection. However, a key role for senescence as a pathogenic driver and potential therapeutic target in other non-SARS-CoV-2 infection-related pathologies, such as other types of viral pneumonia, infectious and non-infectious acute respiratory distress syndrome, as well as non-pulmonary manifestations in viral infections, needs to be determined. A large variety of viruses have been shown to induce senescence in vitro and in vivo\(^\text{7,16,107}\), whereas no VIS phenotype was observed upon infection with the mild seasonal influenza A (H1N1) virus in Syrian hamsters\(^\text{16}\), implying that not all virus infections might be susceptible to senolytic strategies. Although preclinical and first clinical data are encouraging\(^\text{27,28,62,143-145}\), additional clinical studies are required to optimize regimens and dosing schedules. Appropriate timing of such intervention might be important. The preclinical data discussed here support further investigation of senolytic intervention with respect to their anti-inflammatory and pneumonia-attenuating efficacy and to minimize toxicities. Notably, the toxicities of agents with senolytic potential that are approved or currently in clinical trials, such as the tyrosine kinase inhibitor dasatinib or the BCL-2 family inhibitors navitoclax and venetoclax, profoundly differ between the dose/scheduling regimens as used in haemato-oncological indications compared to the regimens tested in preclinical and clinical investigations of COVID-19.

Flavonoids, such as fisetin or quercetin, are freely available 'over-the-counter' agents and have favourable safety profiles\(^\text{169}\). Specifically, in the two COVID-19 trials referred to above, quercetin was generally well tolerated with no apparent toxicity and no particular side effects were reported by the patients\(^\text{163-165}\). Moreover, strategies that combine a senolytic agent with a viral replication blocker, such as Molnupiravir or Paxlovid, or possibly with TLR3 antagonists to attenuate viral induction of senescence appear attractive\(^\text{29}\) as mechanistically distinct approaches to reduce the prevalence of VIS cells may complement each other. However, more definitive preclinical data from SARS-CoV-2-infected animal models are needed to demonstrate that such approaches truly lead to disease attenuation via SASP reduction and not to extended viral persistence owing to impaired virus clearance.

The underlying reasons for the well-established higher risk in the elderly or in individuals with chronic disease to experience severe COVID-19 or to succumb to SARS-CoV-2 infection are multifactorial\(^\text{101}\). As recently shown in mice, the accumulation of (pre-)senescent cells during ageing primes for particularly SAP-intense VIS manifestation upon SARS-CoV-2 infection\(^\text{161}\), even if the senescent status of host cells might suppress further virus propagation as currently debated\(^\text{152,161}\). COVID-19-related VIS may also aggravate age-related pathologies via enhanced SAMP-mediated inflammation\(^\text{153,168}\), as demonstrated for cardiovascular diseases and diabetes in preclinical models\(^\text{170}\), and might further deteriorate immune competence by inducing senescence in immune cells\(^\text{171,172}\). Further analyses into the mechanisms underlying immune cell senescence are urgently needed as is research into general similarities and differences between immune cell senescence and other types of cellular senescence, specifically in the context of immune cell senescence as a paracrine effect of VIS.

Damaged mucosal cells are subject to turnover in their respective tissues, foremost being the respiratory epithelia in the upper and lower airway tract during regeneration after acute COVID-19. More specifically, senescent cells are, at least in part, cleared by cells of both the innate and adaptive immune system\(^\text{65,173-175}\) if such clearing function is not compromised, which remains to be studied in greater detail in the context of COVID-19 (REF\(^\text{176}\)). Persistent senescent cells are known to exert detrimental long-term effects on organ function and can promote
such as p16INK4a or p21CIP1. These proteins induce the expression of central signalling the underlying chronic and destructive VIS operates as a pivotal amplifier of For example, type 1 diabetes mellitus was linked to enterovirus infections and triggers of autoimmune diseases in general. multiple sclerosis to Epstein–Barr virus (EBV) infections. This may imply that VIS operates as a pivotal amplifier of the underlying chronic and destructive autoinflammation in these conditions. EBV infection has long been known to induce the expression of central signalling mediators of the senescence response such as p16INK4a or p21CIP1. These proteins act as a primary host defence against virus propagation, and EBV-positive cells losing expression of these mediators subsequently get selected for in manifest chronic infection. Therefore, research focusing on VIS and SAP in these contexts is urgently needed as it may not only help to elucidate the mechanism of autoaggressive pathogeneses but also to open new therapeutic avenues.

With new insights into COVID-19 pathogenesis and the potential for novel treatment opportunities, a central point has yet to be addressed: what factors, beyond age, determine the strength of the SAPB response in individuals newly infected with SARS-CoV-2? Are predictors of the individual susceptibility to VIS or their senescent cell burden also indicators for a more severe clinical course upon severe COVID-19 infection revealed by single-cell analysis. Pathol. Infect. 11, 589580 (2020).
7. McGonagle, D., Ramanan, A. V. & Bridgewood, C. Immune cartography of macrophage activation syndrome in the COVID-19 era. Nat. Rev. Rheumatol. 17, 145–157 (2021).
8. Vanderbeke, L. et al. Monocyte-driven atypical cytokine storm and abnormal neutrophil activation as key mediators of COVID-19 disease severity. Nat. Commun. 12, 4117 (2021).
9. Mahase, E. Covid-19. Pfizer’s Paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ 375, e2713 (2021).
10. Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451–457 (2021).
11. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA vaccine. N. Engl. J. Med. 383, 2013–2025 (2020).
12. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
13. Fàsely, A. R. et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N. Engl. J. Med. 394, https://doi.org/10.1056/NEJMoa2105290 (2021).
14. Sterne, J. A. C. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324, 1330–1341 (2020).
15. Kyriazopoulou, E. et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen activator light chain levels: a double-blind, randomized controlled phase 3 trial. Nat. Med. 27, 1752–1760 (2021).
16. Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020).
17. Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science https://doi.org/10.1126/science.abb4063 (2021).
18. Roda, L. B. et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell 184, 169–185.e17 (2021).
19. Rydzynski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996–1012.e19 (2021).
20. Reusch, N. et al. Neutrophils in COVID-19. Front. Immunol. 12, 652470 (2021).
21. Roy, R. K. et al. Macrophage activation syndrome and COVID-19: impact of MAPK-driven immunomodulatory programming by SARS-CoV-2. Front. Immunol. 12, 763513 (2021).
22. Toor, S. M., Salesh, R., Sisadasaran Nair, V., Taha, R. Z. & Elkord, E. T-cell responses and therapies against SARS-CoV-2 infection. Immunology 162, 30–43 (2021).
23. Ackermann, M. et al. Pulmonary vascular endotheliopathy, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 385, 120–128 (2021).
24. Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 467–462 (2020).
25. Ren, X. et al. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell 184, 1895–1915.e19 (2021).
26. George, P. M., Wells, A. U. & Jenkins, R. G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir. Med. 8, 807–815 (2020).
27. Camell, C. D. et al. Senolysis reduce coronavirus-related mortality in old mice. Science https://doi.org/10.1126/science.abe4852 (2021).
28. Lee, S. et al. Virus-induced senescence is driven and therapeutic target in COVID-19. Nature https://doi.org/10.1038/s41586-021-03995-1 (2021).
29. Tripathi, U. et al. SARS-CoV-2 causes senescence in human cells and exacerbates the senescence-associated secretory phenotype through TLR-3. Aging 13, 21838–21854 (2021).
30. He, S. & Sharpless, N. E. Senescence in health and disease. Cell 169, 1000–1011 (2017).
31. Herranz, N. & Gil, J. Mechanisms and functions of cellular senescence. J. Clin. Invest. 128, 1238–1248 (2018).
32. Gorgoulis, V. et al. Cellular senescence: defining a path forward. Cell 178, 827–839 (2019).
33. Lee, S. & Schmitt, C. A. The dynamic nature of senescence in cancer. Nat. Cell Biol. 21, 94–101 (2019).
34. Chuprin, A. et al. Cell fusion induced by ERVE1 or measles virus causes cellular senescence. Gene Dev. 27, 2556–2566 (2013).
35. Li, J. et al. Merkel cell polyomavirus large T antigen disrupts host immune integrity and inhibits cellular proliferation. J. Virol. 87, 9175–9188 (2013).
36. Martínez, I. et al. Induction of DNA double-strand breaks by human respiratory syncytial virus. Virology 427, 44–42 (2016).
37. Kohli, J. Venatra, I. S. & Dernaria, M. The struggle of a geriatric cell: cellular senescence in viral responses and therapy. EMBO Rep. 22, e82243 (2021).
38. Seoane, R., Vidal, S., Bouzaher, Y. H., El Motiam, A. & Rivero, C. The interaction of viruses with the cellular senescence response. BioRxiv https://doi.org/10.1101/2021.04.18.114256 (2021).
39. Gong, T., Liu, L., Jiang, W. & Zhou, R. DAMP sensing. Eur. J. Immunol. 50, 416 (2020).
40. Gorwood, J. et al. SIV infection and the HIV proteins Tat and Nef induce senescence in adipose tissue and human adipose stem cells, resulting in adipocyte dysfunction. Cell https://doi.org/10.1016/j.cell.2021.12.040 (2021).
41. Arora, P. et al. B1.617.2 enters and fuses lungs cells with increased efficiency and evades antibodies induced by infection and vaccination. Cell Rep. https://doi.org/10.1016/j.celrep.2021.109825 (2021).
42. Hsieh, T. H. et al. Senescence in monocytes facilitates dendritic cell maturation and increasing infectivity. Front. Cell. Infect. Microbiol. 10, 375 (2020).
43. Marenmanda, K. P., Sundar, I. K., Li, D. & Rahman, I. Age-related downregulation of genes involved in cellular senescence, telomere, and mitochondrial pathways in human lung tissue of smokers, COPD, and COVID-19. Virus 12, e23707 (2020).
44. Decout, A., Katz, J. D., Venkataraman, S. & Ablasser, A. Neutrophil extracellular traps and the HIV proteins Tat and Nef induce senescence in adipose tissue and human adipose stem cells, resulting in adipocyte dysfunction. Cell https://doi.org/10.1016/j.cell.2021.12.040 (2021).
45. Zhao, H. et al. The interaction of viruses with the cellular senescence response. BioRxiv https://doi.org/10.1101/2021.04.18.114256 (2021).
46. Miller, K. N. et al. Cytoplasmic DNA: sources, sensing, and role in aging and disease. Cell 184, 5506–5526 (2021).
47. Acosta, J. C. et al. Chemokine signaling via the CXCR2 receptor relays by an interleukin-dependent inflammatory program the pathogenesis of severe COVID-19. J. Exp. Med. 219, 916–938 (2022).
48. Kirkland, J. L. & Tchkonia, T. Senolytic drugs: from discovery to translation. J. Intern. Med. 288, 518–538 (2020).
49. Garg, G. Muller, K., Zhang, W. & Zhou, R. DAMP sensing receptors in sterile inflammation and inflammatory disease. Nat. Rev. Immunol. 20, 95–112 (2020).
50. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997).
51. Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 666–670 (2005).
52. De Cocco, M. et al. L1 drives IFN in senescent cells and promotes age-associated inlfammatory diseases. Nat. Rev. Immunol. 20, 95–112 (2020).
53. Cortesi, M. G. et al. Aging-associated senescence in human fibroblasts. Aging Cell 19, 286–306 (2020).
54. Yu, Y. et al. Targeting the senescence-overriding cooperative activity of structurally unrelated HSF1 dimerization partners in melanoma. Cancer Cell 33, 322–336 (2018).
55. Michalovich, C. et al. BRAFEGF0-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720–725 (2005).
56. D’Agrillo, F. et al. Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrilolysis, and cellular senescence in fatal COVID-19. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aed7790 (2021).
57. Mårtensson, C. U. et al. Mitochondrial protein translocation in associated degradation. Nature 569, 679–683 (2019).
58. Li, X. et al. Mitochondria shed their outer membrane in response to necrosis-induced stress. Science 375, eabj4354 (2021).
59. Dou, Z. et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature 584, 655–55 (2020).
60. Gluck, S. et al. Innate immune sensing of cytosolic chromatin fragments through cGAS promotes beta2M-dependent antiviral responses in SARS-CoV-2 infected cells. J. Immunol. 201, 1061–1070 (2017).
61. Miller, K. N. et al. Cytoplasmic DNA: sources, sensing, and role in aging and disease. Cell 184, 5506–5526 (2021).
62. Decout, A., Katz, J. D., Venkataraman, S. & Ablasser, A. The cGAS–STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 21, 548–569 (2021).
63. Di Domizio, J. et al. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature 584, 436–452 (2021).
112. Xu, M. et al. Senolytics improve physical function and increase lifespan in old age. *Nat. Med.* 26, 1246–1256 (2018).
113. Robbins, P. D. et al. Senolytic drugs: reducing senescent cell numbers extend health span. *Annu. Rev. Pharmacol. Toxicol.* 61, 779–803 (2021).
114. Tikhonova, T., Palmer, A. K. & Kirkland, J. L. New horizons to enhance healthspan through targeting cellular senescence and related aging mechanisms. *J. Clin. Endocrinol. Metab.* 106, e130–e139 (2021).
115. Lubin, J. H. et al. Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces. *Preprint* https://doi.org/10.1101/2021.12.21.272315 (2021).
116. Karakasiliotis, I., Lagopati, N., Evangelou, K. & Gorgoulis, V. G. Cellular senescence as a source of SARS-CoV-2 quasispecies. *FEBS J.* https://doi.org/10.1111/febs.16250 (2021).
117. Verma, A. K. & Aggarwal, R. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm. *Chem. Biol. Drug Des.* 97, 836–853 (2021).
118. Colunga Biancatti, R. M. L., Berrill, M., Catravas, J. D. & Manek, P. E. Quercetin and vitamin C: an experimental, synergistic, and effective approach for prevention and treatment of SARS-CoV-2 related disease (COVID-19). *Front. Immunol.* 11, 1451 (2020).
119. Mohiuddin, M. & Kasahara, K. The emerging role of cellular senescence in complications of COVID-19. *Cancer Treat. Res.* 228, 100359 (2021).
120. Xu, Q. et al. How quercetin protects against COVID-19? *Molecules* 25, 1542 (2020).
121. Zhao, J., Zhao, J., Legge, K. & Perlman, S. Age-related cellular senescence and immune aging. *Nature* 575, 1124–1127 (2019).
122. Robbins, P. D. et al. Senolytic drugs: reducing senescent cell numbers extend health span. *Nat. Med.* 26, 1246–1256 (2021).
123. Wang, C. et al. Senescence-activated secretory phenotype and clinical implications of senescence and senotherapies. *Cancer Med.* 9, 106 (2020).
124. Kreye, J. et al. Potential clinical benefits of adjuvant quercetin supplementation against early-stage COVID-19 infection: a prospective, randomized, controlled,安慰剂对照研究. *Int. J. Mol. Med.* 46, 2359–2366 (2021).
125. Di Pierso, F. et al. Potential clinical benefits of quercetin in patients with SARS-CoV-2 infection: results of a second, pilot, randomized, controlled and open-label clinical trial. *Int. J. Mol. Med.* 46, 2807–2816 (2021).
126. Schneider, J. L. et al. Lung, physiology, disease, and immunity. *Cell* 178, 1990–2019 (2019).
127. Justice, J. N. et al. Senolics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. *J. Interferon Cytokine Res.* 49, 554–565 (2019).
128. Verdoorn, B. P. et al. Fisetin for COVID-19 in skilled nursing facilities: senolytic trials in the COVID era. *Annu. Rev. Pharmacol. Toxicol.* https://doi.org/10.1146/annurev-pharmtox-041020-091333 (2021).
129. Chab, S., Tikhonova, T. & Kirkland, J. L. Obesity, senescence, and the adaptive immune system. *Exp. Physiol.* Soc. https://doi.org/10.1113/epjope.107.1741 (2021).
130. Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. *Nature* 586, 567–571 (2020).
131. Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. *N. Engl. J. Med.* https://doi.org/10.1056/NEJMc2119641 (2021).
132. Mulligan, M. J. et al. Phase 1/2 study of COVID-19 mRNA vaccine BNT162b1 in adults. *Eur. J. Med. Chem.* 212, 2002–2013 (2020).
133. Schmidt, F. et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. *Sci. Transl. Med.* https://doi.org/10.1126/scitranslmed.abj8222 (2022).
134. Arora, S. et al. Invariant natural killer T cells: a new cellular coordinate removal of senescent cells. *Med.* 2, 938–950 (2021).
135. Knoll, P. L., Schultz, J. L. & Schulte-Schporren, J. Monocytes and macrophages in COVID-19. *Front. Immunol.* 12, 720109 (2021).
136. Marianow, M. et al. Senescence-associated reprogramming promotes cancer stemness. *Nature* 553, 96–100 (2018).
137. Wyld, L. et al. Senescence and cancer: a review of clinical implications of senescence and senotherapies. *Cancers* https://doi.org/10.3390/cancers101220814 (2020).
138. Mandell, M. The four most urgent questions about long COVID. *Nature* 594, 168–170 (2021).
139. Nalbandian, A. et al. Post-acute COVID-19 syndrome. *Nat. Rev. Dis. Primers* 7, 594 (2021).
140. Sfera, A. et al. Endothelial senescence and chronic fatigue syndrome, a COVID-19 based hypothesis. *Front. Cell. Neurosci.* 15, 775 (2021).
141. Avanzato, V. A. et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. *Cell* 183, 1991–1912 (2021).
142. Galeotti, C. & Bavyr, J. Autoimmune and inflammatory diseases following COVID-19. *Nat. Rev. Rheumatol.* 16, 413–414 (2020).
143. Kaklamanos, A. et al. COVID-19 immunobiology: lessons learned, new questions arise. *Front. Immunol.* 12, 719005 (2021).
144. Op de Beek, A. & Euzirik, D. L. Viral infections in type 1 diabetes mellitus—why the cells? *Nat. Rev. Endocrinol.* 17, 525–537 (2021).
145. Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis occurrence. *Cell Host Microbe* https://doi.org/10.1016/j.chom.2022.02.008 (2022).
146. Yang, X., He, Z., Xin, B. & Cao, Y. LMP1 of Epstein- Barr virus suppresses cellular senescence associated with inhibition of p53/FOXO4 expression. *Oncogene* 19, 2002–2013 (2020).
147. Chen, Y. L. et al. The Epstein-Barr virus replication and transcription activator, EBNA-1 induces cellular senescence in epithelial cells. *Cell Cycle* 8, 58–65 (2009).
148. Dalholt, P. A. et al. Seroconversion and fever are dose-dependent in a human non-primate model of inhalational COVID-19. *PLoS Pathog.* 17, e1008965 (2021).
Huff, L. E. & Moorhead, P. S. The limited in vitro lifetime of human diploid cell strains. *Exp. Cell Res.* 25, 585–621 (1961).

190. Yu, C. L., Bradley, J. D., Attardi, L. D. & Blackburn, E. H. In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs. *Nature* 344, 126–132 (1990).

191. Munoz-Espin, D. et al. Programmed cell senescence during mammalian embryonic development. *Cell* 155, 1104–1118 (2013).

192. Storer, M. et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. *Cell* 155, 1119–1130 (2013).

193. Demaria, M. et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. *Dev. Cell* 31, 722–733 (2014).

194. Ike, J. et al. Senolitics prevent mt-DNA-induced inflammation and promote the survival of aged organs following transplantation. *Nat. Commun.* 11, 4289 (2020).

195. Prata, L., Ovsyannikova, I. G., Tkchonia, T. & Kirkland, J. L. Senescent cell clearance by the immune system: emerging therapeutic opportunities. *Semin. Immunol.* 40, 101275 (2018).

196. Mosteiro, L. et al. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. *Science* https://doi.org/10.1126/science.aaf4445 (2016).

197. Ritchka, B. et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. *Genes Dev.* 31, 172–183 (2017).

198. Beausjour, C. M. et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. *EMBO J.* 22, 4212–4222 (2003).

199. Minamino, T. et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. *Nat. Med.* 15, 1082–1087 (2009).

200. Aird, K. M. et al. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. *Cell Rep.* 3, 1252–1263 (2013).

201. Palmer, A. K. et al. Targeting senescent cells alleviates obesity-induced metabolic dysfunction. *Aging Cell* 18, e12950 (2019).

202. Schmitt, C. A. et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. *Cell* 109, 535–546 (2002).

203. Collins, M. et al. Tumour biology: senescence in premalignant tumours. *Nature* 436, 642 (2005).

204. Prasanna, P. G. et al. Therapy-induced senescence: opportunities to improve anticancer therapy. *J. Natl Cancer Inst.* 113, 1285–1298 (2021).

205. Young, A. R. & Nairn, A. Spatio-temporal association between mTOR and autophagy during cellular senescence. *Autophagy* 7, 1587–1588 (2013).

206. Dorr, J. R. et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. *Nature* 501, 421–425 (2013).

207. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc. Natl Acad. Sci. USA* 92, 9363–9367 (1995).

208. Sharpless, N. E. & Sherr, C. J. Forging a signature of in vivo senescence. *Nat. Rev. Cancer* 15, 397–408 (2015).

209. Fan, D. N. Y. & Schmitt, C. A. Genotoxic stress-induced senescence. *Methods Mol. Biol.* 1896, 95–105 (2019).

210. Nairn, A. et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. *Cell* 113, 705–716 (2003).

211. Zhang, R. et al. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASFa1 and HIRA. *Dev. Cell* 8, 19–30 (2005).

212. Chandra, T. et al. Global reorganization of the nuclear landscape in senescent cells. *Cell Rep.* 10, 471–483 (2015).

213. De Cecco, M. et al. Genomes of replicatively senescent cells undergo global epigenetic changes leading to gene silencing and activation of transposable elements. *Aging Cell* 12, 247–256 (2013).

214. Sadaei, M. et al. Redistribution of the Lamin B1 genomic binding profile affects rearrangement of heterochromatic domains and SAHF formation during senescence. *Genes Dev.* 27, 1800–1808 (2013).

215. Shah, P. P. et al. Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape. *Genes Dev.* 27, 1787–1799 (2013).

216. Tsatsopoulou, N. et al. BRD4 connects enhancer remodeling to senescence immune surveillance. *Cancer Discov.* 6, 612–629 (2016).

217. Martinez-Zamudio, R. I. et al. AP-1 imprints a reversible transcriptional programme of senescent cells. *Nat. Cell Biol.* 22, 842–855 (2020).

Acknowledgements
The authors apologize to all colleagues whose valuable insights and contributions to the discussed topics may have been missed or not explicitly mentioned owing to space restrictions. The authors thank numerous funding sources that enabled research at the intersection of senescence and COVID-19 in their laboratories, members of their research teams as well as their collaboration partners for helping scientific exchange of conceptual ideas, controversies in the field, and clinical implications, as well as all the patients and their families, whose participation in clinical investigations and trials enhance our knowledge of pathogenetic mechanisms and therapeutic interventions.

Author contributions
The authors contributed equally to all aspects of the article.

Competing interests
C.A.S. received travel support, honoraria and consulting fees from Abbvie, AstraZeneca, Bayer, Bristol-Myers Squibb/Celgene, Gilead/Kite, Janssen-Cilag, MSD, Novartis, Octapharma, Pierre Fabre, Roche, Sanofi, Takeda, and TissUse. Patents on senolitic drugs and their uses are held by Mayo Clinic (J.L.K. and T.T.) and the University of Minnesota (P.D.R. and L.J.N.). S.L. declares no competing interests.

Peer review information
Nature Reviews Immunology thanks Henrikke Maass who co-reviewed with Luca Cicc-Sain, Jesus Gill and the other, anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

© Springer Nature Limited 2022